Industry mourns loss of former Costco exec Charles Burnett
Charles “Charlie” Burnett, a longtime Costco pharmacy executive, passed away early in the morning on June 1, the National Association of Chain Drug Stores announced Friday. Burnett is being remembered for his work as a pharmacy pioneer who helped build and grow Costco’s pharmacy business.
During his lifetime, Burnett became the only person to win both of NACDS’ highest honors — the Sheldon W. Fantle Lifetime Achievement Award and the Harold W. Pratt Award.
“Although he retired from Costco in 2013, Charlie’s pioneering work for our pharmacies continues to contribute to our company’s success,” Costco SVP pharmacy Vic Curtis, who informed the industry of Burnett’s passing, wrote. “It has been an honor and a pleasure to have known and worked with Charles Burnett for the past 26 years and I often reflect on his unique contributions to our profession and his ethical and honest style of conducting business.”
Burnett was a veteran of the U.S. military and had been in the pharmacy industry since the 1950s — working with Save Mart Supermarkets and FedMart before eventually spending time at Costco building and expanding its pharmacy business, overseeing its first pharmacy opening in 1986, as well as the opening and operations of some 500 other locations.
“I distinctly remember how it felt to see Charlie win the Fantle Award in 2010, and the Pratt Award in 2007,” NACDS president and CEO Steve Anderson said. “Both presentations were true celebrations of extraordinary dedication, accomplishment, friendship and class. The loss of Charlie will be felt by so many people whose lives he affected so positively and so deeply. We stand with Barbara and their family, with the extended Costco family, and with their dear friends, in remembering Charlie warmly, and giving thanks for his amazing life.”
No information about arrangements was available Friday afternoon.
NACDS, APhA caution Trump administration on drug importation
WASHINGTON — The National Association of Chain Drug Stores and the American Pharmacists Association this week urged the Trump administration to steer clear of legislation that would clear the way for the importation of prescription drugs from other countries.
The two penned a letter calling on Pres. Trump and administration officials to “refrain from endorsing pending legislative proposals that would allow for broad personal and commercial importation of non-[Food and Drug Administration (FDA)] approved prescription drugs.”
The letter noted importation’s risks associated with counterfeit drugs, and specifically the risk of undermining the 2013 Drug Supply Chain Security. NACDS and APhA highlighted extensive documentation of concerns expressed by the FDA and by Canadian authorities.
“Throughout the past 15 years, through speeches, testimony, letters and other consumer resources, FDA has repeatedly sounded the alarm on the risk to patient safety posed by importation of non-FDA approved drugs,” the letter said.
The two organization emphasized that importation would serve to undermine two key elements of pharmacy-led care — the pharmacist-patient relationship and the delivery of value-based care.
“Value-based care models and other efforts to produce savings and promote quality, such as outcomes-based reimbursement, will be more difficult to measure and optimize if patients are allowed to receive care outside the model’s mechanisms to drive results,” they said.
To read the full letter, click here.